Our First Five Years: 2013-2017

A compelling growth story. A strong investment. A rapidly advancing pipeline.

Our Five Year Performance

In our first five years as AbbVie, we have delivered on our commitment to turn robust investment in scientific research into a pipeline of promising treatments. We invite you to take a closer look at our performance over the past five years. For a complete look at our 2017 performance, our earnings press release is located here.

Robust and Productive Pipeline

AbbVie’s late-stage pipeline is strong across several therapeutic areas, and is producing a consistent stream of innovative medicines and positioning us to continue to meet the needs of patients we serve and ensure growth over the long term.

* Revenue from new oncology, virology and neuroscience products launched since 2013 totaled more than $4.2 billion in 2017.

* 2017 GAAP R&D investment of $5.0B, +72% over 2013 GAAP R&D investment of $2.9B.

Pipeline Compounds

AbbVie has built a strong pipeline of experimental therapies, including several new medicines in late-stage human studies. Currently, AbbVie has 70 clinical programs in development across our entire portfolio.

Strong Return on Capital

AbbVie’s revenue and earnings have grown each year since inception, enabling the company to raise its dividend by 78% and achieve a total return of 238.5%.*

* As of December 31, 2017

Where We’re Going

For us, the future is always present, filled with the potential for advancing science and patient care. Science and innovation are the cornerstones of our business. We remain focused on discovering and delivering medicines where we have proven expertise and can make a remarkable impact.

For Investor and Media Use Only - Not For Promotional Use